High-Dose Nusinersen Regimen Shows Improved Motor Function in Spinal Muscular Atrophy Patients

The results of the pivotal DEVOTE study evaluating a high-dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA) have been published in *Nature Medicine*. The study investigated the safety and efficacy of an increased dosage of nusinersen compared to the standard dose currently used in clinical practice. Researchers aimed to determine whether higher doses could provide enhanced therapeutic benefits for individuals with SMA, a rare genetic disorder that affects muscle strength and movement.

The findings from the study demonstrated that the high-dose regimen was generally well-tolerated among participants. Data showed improvements in motor function across several measures, including motor milestone achievements and upper limb strength, particularly in patients who transitioned from the standard dose to the higher dose. The study also reported no new safety concerns associated with the increased dosage. These results contribute to ongoing research into optimizing treatment strategies for SMA patients and may inform future clinical approaches.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: February 4, 2026

Author

GOAI